|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PABPC1L |
Gene summary for PABPC1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PABPC1L | Gene ID | 80336 |
| Gene name | poly(A) binding protein cytoplasmic 1 like | |
| Gene Alias | C20orf119 | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80336 | PABPC1L | HCC1_Meng | Human | Liver | HCC | 7.29e-28 | 1.26e-01 | 0.0246 |
| 80336 | PABPC1L | HCC1 | Human | Liver | HCC | 8.30e-21 | 5.02e+00 | 0.5336 |
| 80336 | PABPC1L | HCC2 | Human | Liver | HCC | 5.94e-18 | 4.73e+00 | 0.5341 |
| 80336 | PABPC1L | S014 | Human | Liver | HCC | 4.84e-02 | 2.45e-01 | 0.2254 |
| 80336 | PABPC1L | S015 | Human | Liver | HCC | 2.37e-02 | 3.66e-01 | 0.2375 |
| 80336 | PABPC1L | S016 | Human | Liver | HCC | 1.91e-06 | 3.66e-01 | 0.2243 |
| 80336 | PABPC1L | S028 | Human | Liver | HCC | 2.63e-11 | 5.18e-01 | 0.2503 |
| 80336 | PABPC1L | S029 | Human | Liver | HCC | 3.29e-08 | 5.53e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa0301521 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa0301531 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PABPC1L | SNV | Missense_Mutation | novel | c.95C>A | p.Ser32Tyr | p.S32Y | Q4VXU2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| PABPC1L | SNV | Missense_Mutation | c.361N>G | p.Thr121Ala | p.T121A | Q4VXU2 | protein_coding | tolerated(1) | benign(0.007) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PABPC1L | SNV | Missense_Mutation | rs372472103 | c.1048N>A | p.Val350Met | p.V350M | Q4VXU2 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| PABPC1L | SNV | Missense_Mutation | novel | c.79C>A | p.Leu27Ile | p.L27I | Q4VXU2 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PABPC1L | SNV | Missense_Mutation | novel | c.286N>C | p.Ser96Pro | p.S96P | Q4VXU2 | protein_coding | deleterious(0) | possibly_damaging(0.817) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PABPC1L | SNV | Missense_Mutation | rs763727369 | c.815N>A | p.Arg272Gln | p.R272Q | Q4VXU2 | protein_coding | deleterious(0.01) | possibly_damaging(0.872) | TCGA-D1-A17M-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PABPC1L | SNV | Missense_Mutation | c.216N>T | p.Met72Ile | p.M72I | Q4VXU2 | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PABPC1L | SNV | Missense_Mutation | novel | c.965G>A | p.Ser322Asn | p.S322N | Q4VXU2 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-D1-A1NZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PABPC1L | SNV | Missense_Mutation | rs374095444 | c.248G>A | p.Arg83His | p.R83H | Q4VXU2 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| PABPC1L | SNV | Missense_Mutation | novel | c.91T>C | p.Phe31Leu | p.F31L | Q4VXU2 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |